Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Piotr Milkiewicz

Showing results (141-150 of 197) with videos related to

Pageof 20
Sort By:
International Journal of Molecular Sciences|July 26, 2016
Nutritional Strategies for the Individualized Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) Based on the Nutrient-Induced Insulin Output Ratio (NIOR)Ewa Stachowska, Karina Ryterska, Dominika Maciejewska, et al.
European Journal of Clinical Investigation|May 29, 2021
Mitochondria, oxidative stress and nonalcoholic fatty liver disease: A complex relationshipAgnieszka Karkucinska-Wieckowska, Ines C M Simoes, Piotr Kalinowski, et al.
Scientific Reports|December 24, 2021
MARC1 p.A165T variant is associated with decreased markers of liver injury and enhanced antioxidant capacity in autoimmune hepatitisMaciej K Janik, Wiktor Smyk, Beata Kruk, et al.
Frontiers in Immunology|April 20, 2019
The Prevalence of Anti-Hexokinase-1 and Anti-Kelch-Like 12 Peptide Antibodies in Patients With Primary Biliary Cholangitis Is Similar in Europe and North America: A Large International, Multi-Center StudyGary L Norman, Anna Reig, Odette Viñas, et al.
Alimentary Pharmacology & Therapeutics|January 24, 2019
Review article: unanswered clinical and research questions in autoimmune hepatitis-conclusions of the International Autoimmune Hepatitis Group Research WorkshopJessica K Dyson, Eleonora De Martin, George N Dalekos, et al.
The Lancet. Gastroenterology & Hepatology|October 13, 2025
Fatigue in people with primary biliary cholangitis: a position paper from the European Reference Network for Rare Liver DiseasesOzgur M Koc, Anne-Kristin Toussaint, Aurelie Untas, et al.
Plos One|November 15, 2014
PR3-ANCA: a promising biomarker in primary sclerosing cholangitis (PSC)Laura M Stinton, Chelsea Bentow, Michael Mahler, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|February 6, 2024
Oxidative stress in metabolic dysfunction-associated steatotic liver disease (MASLD): How does the animal model resemble human disease?Patrycja Jakubek, Piotr Kalinowski, Agnieszka Karkucinska-Wieckowska, et al.
JHEP Reports : Innovation in Hepatology|October 21, 2022
Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitisChristoph Schramm, Heiner Wedemeyer, Andrew Mason, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|June 9, 2024
Loss of mucosal tolerance to glycoprotein 2 isoform 1 is a potential novel diagnostic biomarker for cholangiocarcinomaChang-Sheng Xia, Marcin Krawczyk, Chun Di, et al.
Pageof 20

Showing results (141-150 of 197) with videos related to

Sort By:
Pageof 20
International Journal of Molecular Sciences|July 26, 2016
Nutritional Strategies for the Individualized Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) Based on the Nutrient-Induced Insulin Output Ratio (NIOR)Ewa Stachowska, Karina Ryterska, Dominika Maciejewska, et al.
European Journal of Clinical Investigation|May 29, 2021
Mitochondria, oxidative stress and nonalcoholic fatty liver disease: A complex relationshipAgnieszka Karkucinska-Wieckowska, Ines C M Simoes, Piotr Kalinowski, et al.
Scientific Reports|December 24, 2021
MARC1 p.A165T variant is associated with decreased markers of liver injury and enhanced antioxidant capacity in autoimmune hepatitisMaciej K Janik, Wiktor Smyk, Beata Kruk, et al.
Frontiers in Immunology|April 20, 2019
The Prevalence of Anti-Hexokinase-1 and Anti-Kelch-Like 12 Peptide Antibodies in Patients With Primary Biliary Cholangitis Is Similar in Europe and North America: A Large International, Multi-Center StudyGary L Norman, Anna Reig, Odette Viñas, et al.
Alimentary Pharmacology & Therapeutics|January 24, 2019
Review article: unanswered clinical and research questions in autoimmune hepatitis-conclusions of the International Autoimmune Hepatitis Group Research WorkshopJessica K Dyson, Eleonora De Martin, George N Dalekos, et al.
The Lancet. Gastroenterology & Hepatology|October 13, 2025
Fatigue in people with primary biliary cholangitis: a position paper from the European Reference Network for Rare Liver DiseasesOzgur M Koc, Anne-Kristin Toussaint, Aurelie Untas, et al.
Plos One|November 15, 2014
PR3-ANCA: a promising biomarker in primary sclerosing cholangitis (PSC)Laura M Stinton, Chelsea Bentow, Michael Mahler, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|February 6, 2024
Oxidative stress in metabolic dysfunction-associated steatotic liver disease (MASLD): How does the animal model resemble human disease?Patrycja Jakubek, Piotr Kalinowski, Agnieszka Karkucinska-Wieckowska, et al.
JHEP Reports : Innovation in Hepatology|October 21, 2022
Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitisChristoph Schramm, Heiner Wedemeyer, Andrew Mason, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|June 9, 2024
Loss of mucosal tolerance to glycoprotein 2 isoform 1 is a potential novel diagnostic biomarker for cholangiocarcinomaChang-Sheng Xia, Marcin Krawczyk, Chun Di, et al.
Pageof 20